These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25454732)

  • 41. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy.
    Mayhew AG; Moat D; McDermott MP; Eagle M; Griggs RC; King WM; James MK; Muni-Lofra R; Shillington A; Gregson S; Pallant L; Skura C; Staudt LA; Eichinger K; McMurchie H; Rabb R; Di Marco M; Brown S; Zanin R; Arnoldi MT; McIntyre M; Wilson A; Alfano LN; Lowes LP; Blomgren C; Milev E; Iodice M; Pasternak A; Chiu A; Lehnert I; Claus N; Dieruf KA; Rolle E; Nicorici A; Andres B; Hobbiebrunken E; Roetmann G; Kern V; Civitello M; Vogt S; Hayes MJ; Scholtes C; Lacroix C; Gunn T; Warner S; Newman J; Barp A; Kundrat K; Kovelman S; Powers PJ; Guglieri M;
    Neuromuscul Disord; 2022 Jun; 32(6):460-467. PubMed ID: 35618576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F;
    Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cumulative jerk as an outcome measure in nonambulatory Duchenne muscular dystrophy.
    Fujii T; Takeshita E; Iwata Y; Yajima H; Nozaki F; Mori M; Kumada T
    Brain Dev; 2019 Oct; 41(9):796-802. PubMed ID: 31213334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls.
    Muntoni F; Signorovitch J; Sajeev G; Goemans N; Wong B; Tian C; Mercuri E; Done N; Wong H; Moss J; Yao Z; Ward SJ; Manzur A; Servais L; Niks EH; Straub V; de Groot IJ; McDonald C;
    Neuromuscul Disord; 2022 Apr; 32(4):271-283. PubMed ID: 35396092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey.
    Senesac CR; Lott DJ; Willcocks RJ; Duong T; Smith BK
    J Neuromuscul Dis; 2019; 6(1):75-83. PubMed ID: 30562905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.
    Ayyar Gupta V; Pitchforth JM; Domingos J; Ridout D; Iodice M; Rye C; Chesshyre M; Wolfe A; Selby V; Mayhew A; Mazzone ES; Ricotti V; Hogrel JY; Niks EH; de Groot I; Servais L; Straub V; Mercuri E; Manzur AY; Muntoni F;
    PLoS One; 2023; 18(4):e0283669. PubMed ID: 37099511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy.
    Yin L; Xie ZY; Xu HY; Zheng SS; Wang ZX; Xiao JX; Yuan Y
    Curr Med Sci; 2019 Feb; 39(1):138-145. PubMed ID: 30868504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance.
    Oreto L; Vita GL; Mandraffino G; Carerj S; Calabrò MP; Manganaro R; Cusmà-Piccione M; Todaro MC; Sframeli M; Cinquegrani M; Toscano A; Vita G; Messina S; Zito C
    Acta Myol; 2020 Dec; 39(4):191-199. PubMed ID: 33458574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information?
    Vill K; Ille L; Schroeder SA; Blaschek A; Müller-Felber W
    Eur J Paediatr Neurol; 2015 Nov; 19(6):640-6. PubMed ID: 26455815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy.
    Heberer K; Fowler E; Staudt L; Sienko S; Buckon CE; Bagley A; Sison-Williamson M; McDonald CM; Sussman MD
    Gait Posture; 2016 Jul; 48():159-164. PubMed ID: 27267770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.
    Kinali M; Mercuri E; Main M; Muntoni F; Dubowitz V
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S169-74. PubMed ID: 12206813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and content validation of the Muscular Dystrophy Child Health Index of Life with Disabilities questionnaire for children with Duchenne muscular dystrophy.
    Propp R; McAdam L; Davis AM; Salbach NM; Weir S; Encisa C; Narayanan UG
    Dev Med Child Neurol; 2019 Jan; 61(1):75-81. PubMed ID: 30058069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy.
    Connolly AM; Malkus EC; Mendell JR; Flanigan KM; Miller JP; Schierbecker JR; Siener CA; Golumbek PT; Zaidman CM; Mcdonald CM; Johnson L; Nicorici A; Karachunski PI; Day JW; Kelecic JM; Lowes LP; Alfano LN; Darras BT; Kang PB; Quigley J; Pasternak AE; Florence JM;
    Muscle Nerve; 2015 Apr; 51(4):522-32. PubMed ID: 25056178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.
    Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up.
    Coratti G; Pane M; Brogna C; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Hogrel JY; Straub V; De Lucia S; Niks E; Servais L; De Groot I; Chesshyre M; Bertini E; Goemans N; Muntoni F; Mercuri E;
    PLoS One; 2021; 16(6):e0253882. PubMed ID: 34170974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).
    Ciafaloni E; Fox DJ; Pandya S; Westfield CP; Puzhankara S; Romitti PA; Mathews KD; Miller TM; Matthews DJ; Miller LA; Cunniff C; Druschel CM; Moxley RT
    J Pediatr; 2009 Sep; 155(3):380-5. PubMed ID: 19394035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy.
    Thongsing A; Likasitwattanakul S; Sanmaneechai O
    Health Qual Life Outcomes; 2019 May; 17(1):76. PubMed ID: 31046775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.